Head of Marketing and Applications Development for a spatial transcriptomic company.

EMEA Marketing Manager for large corporate dental accounts. B to B to C marketing with corporate partners such as Bupa Dental care and Colosseum. This was a new channel set up, within align. Please note Align technology has moved to CH hence the short tenure, I come fully recommend.

Analysis and segmentation of patient association, pharmaceutical partners and other stakeholders for market entry partnerships and go-to-market

Strategy: Contributed to the Light and Health Venture strategy via product road mapping, business plans/models, channel strategy and activation Patient Advocacy: Worked with influential patient associations to create shared valueGo-to-Market: Development of market entry strategies including value chain analysis for new products/markets. Created business cases and performed market research. Commercialized products via a network of distributors. Social Media: Identified, ranked and contracted relationships with influential vloggers/bloggers.Created Patient testing groups integrate into digital social campaigns, and product specification upgrades Brand Development: Creator/manager @PhilipsBlueLED twitter community , segmented and grew community around psoriasis, positive impact on sales Healthcare Key Account Manager: Attended all relevant congresses to drive adoption and growth. Key Opinion Leader management, pharmacy contracting Teamwork: Collaborated with Marketing, R&D and relevant parties to effectively build/apply scientific claims, contribute to the process of obtaining key regulatory/reimbursement approvals

Segment: Gastroenterology Product: Lialda/ Pentasa Rank: Moved volume/share from no performance to 92% to goal in 4 months ending the year at plan Course Work: Top 10% for all product knowledge, Ulcerative Colitis and IBD

Segment: Nephrology, Cardiology Renal Dietitians, Social Workers, UCLA, Cedars, Davita, and Fresenius dialysis centersProduct: Fosrenal phosphate binding for end stage renal disease Market Share: Currently moved volume/share from under-performance to 118% to goal in 3 months, ending the year at 120% to goalCourse Work: Top 10% for all product knowledge

Segment: Psychiatry, Oncology, Orthopedic, Pain, Anesthesiology, Endocrinology, Pulmonary & University Hospitals (USC)using the GAP, PIQL & PSSRx selling styles. Product: Launch of Lunesta, Xopenex HFA, & BrovanaRanked: 3 out 40 Teams - Course Work: Consistently Scores in the top 5%

Segment: GPs, IM, Orthropedic, Neurology, Military and State accounts Products: Celebrex, Bextra, Relpax Market Share: Increased market share from zero to .7% in a congested market within a 2 months bydeveloping relationships, organizing in-service displays, speaker programs and extended lunchesRank: --Was able to switch patients with minimal loss during international recall of Bextra --Left Pfizer 5th in Nation out of 1,060 representatives, 1st in the Region out of 560 reps, and 1st in the District out of 10 reps